News Perspectives

New Cholesterol Drugs: Big Promise, Big Price

Some powerful new cholesterol-lowering drugs may be available soon. But before you run to your doctor, know this: The new drugs will be expensive and require a daily injection. Alirocumab (Praluent) and evolocumab (Repatha) belong to a new class of drugs called PCSK9 inhibitors. They work differently than the popular — and cheap — statin drugs that are commonly prescribed to lower cholesterol. Of course, the goal of lowering cholesterol is to cut the risk of heart attacks and strokes. The statin approach is a bargain. But for people at a higher risk of heart attack, the new drugs, while costly, may offer better protection. HealthDay News wrote about this story on June 11.     

To continue reading this article you must be registered.

Get Licensed Content to Harvard Health

If you are interested in licensing content from Harvard Health Publications, please contact us using our online form. Our licensing and business development professionals will help you leverage consumer health content from Harvard Medical School as a clear differentiator in helping achieve your business goals.

Contact Us

Customer Log In